[go: up one dir, main page]

KR900701307A - Antiviral or antibacterial compounds and methods of using the same - Google Patents

Antiviral or antibacterial compounds and methods of using the same

Info

Publication number
KR900701307A
KR900701307A KR1019900700132A KR900700132A KR900701307A KR 900701307 A KR900701307 A KR 900701307A KR 1019900700132 A KR1019900700132 A KR 1019900700132A KR 900700132 A KR900700132 A KR 900700132A KR 900701307 A KR900701307 A KR 900701307A
Authority
KR
South Korea
Prior art keywords
composition
dimer
treating
effective amount
carrier
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
KR1019900700132A
Other languages
Korean (ko)
Other versions
KR930004599B1 (en
Inventor
위톨드 킥즈카
Original Assignee
원본미기재
니카 헬쓰 케어 인코포레이션
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 원본미기재, 니카 헬쓰 케어 인코포레이션 filed Critical 원본미기재
Priority claimed from PCT/US1988/001785 external-priority patent/WO1989011294A1/en
Publication of KR900701307A publication Critical patent/KR900701307A/en
Application granted granted Critical
Publication of KR930004599B1 publication Critical patent/KR930004599B1/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

내용 없음No content

Description

항 비루스성 또는 항 박테리아성 화합물과 그 사용방법Antiviral or antibacterial compounds and methods of using the same

본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음Since this is an open matter, no full text was included.

Claims (26)

활성성분으로서 리소짐 이합체와 리보핵산 분해효소 이합체로 구성된 그룹으로부터 선택된 이합체와 제약에 수용할 수 있는 담체로 이루어진 항비루스성 흑은 항박테리아성 조성물.An antiviral black and antibacterial composition comprising a dimer selected from the group consisting of a lysozyme dimer and a ribonuclease dimer as an active ingredient and a carrier that can be accommodated in pharmaceuticals. 제1항에 있어서, 이합체가 리소짐 이합체임을 특징으로 하는 조성물.The composition of claim 1, wherein the dimer is a lysozyme dimer. 제1항에 있어서, 그 이합체가 리보핵산 분해효소 이합체임을 특징으로 하는 조성물.The composition of claim 1, wherein the dimer is a ribonuclease dimer. 제3항에 있어서, 그 이합체가 췌장 리보핵산 분해효소 A이합체임을 특징으로 하는 조성물.4. The composition according to claim 3, wherein the dimer is a pancreatic ribonuclease A dimer. 제1항에 있어서, 제약에 수용할 수 있는 담체가 친수성 염기임을 특징으로 하는 조성물.The composition of claim 1 wherein the carrier that is acceptable to the pharmaceutical is a hydrophilic base. 제1항에 있어서, 제약에 수용할 수 있는 담체가 0. 5-1.5%염화나트륨 수용액임을 특징으로 하는 조성물.The composition of claim 1, wherein the carrier that can be accommodated in pharmaceuticals is an aqueous solution of 0.5-1.5% sodium chloride. 사람 흑은 동물환자에게 제1항에 따른 조성물을 효과적인 양만큼 투여함으로 이루어지는 비루스성 또 박테리아성 감염을 치료하는 방법.A method of treating human and bacterial infections comprising administering to the animal patient an effective amount of the composition of claim 1. 사람 혹은 동물환자에게 제1항에 따른 조성물을 효과적인 양만큼 투여함으로 이루어지는 세포 독성작용없이 비루스성 또는 박테리아성 감염을 효소적으로 치료하는 방법.A method of enzymatically treating a viral or bacterial infection without the cytotoxic effect of administering an effective amount of the composition according to claim 1 to a human or animal patient. 제7항에 있어서, 그 조성물을 체중 kg당 약 0.01에서 50mg의 양만큼 투여함을 특징으로 하는 방법.8. The method of claim 7, wherein the composition is administered in an amount of about 0.01 to 50 mg per kg body weight. 제7항에 있어서, 그 조성물을 구강을 통해 투여함을 특징으로 하는 방법.8. The method of claim 7, wherein the composition is administered via the oral cavity. 제7항에 있어서, 그 조성물을 정맥을 통해 투여함을 특징으로 하는 방법.8. The method of claim 7, wherein the composition is administered intravenously. 사람 혹은 동물환자에게 제1항에 따른 조성물을 효과적인 양만름 국소적으로 투여함으로 이루어지는 비루스성 또는 박테리아성 피부질환을 치료하는 방법.A method of treating viral or bacterial skin disease, which is achieved by topically administering a composition according to claim 1 to a human or animal patient. 제12항에 있어서, 그 조성물을 연고제의 형태로 환자에게 투여함을 특징으로 하는 항법.The method of claim 12 wherein the composition is administered to the patient in the form of an ointment. 제12항에 있어서, 그 조성물을 생리적 수용 염용액의 형태로 투여함을 특징으로 하는 방법.13. The method of claim 12, wherein the composition is administered in the form of a physiologically acceptable salt solution. 제14항에 있어서, 그 염용액이 0.5-1.5% 염화나트륨 용액잉을 특징으로 하는 방법15. The method of claim 14, wherein the salt solution is characterized by 0.5-1.5% sodium chloride solution. 제1항에 따른 조성물을 효과적인 양만큼 감염부위에 국소적으로 바름으로써 이루어지는 혜르페스(herpes)를 치료하는 방법.A method for treating herpes, which is achieved by topically applying the composition of claim 1 to an infected area in an effective amount. 제1항에 따른 조성물을 효과직인 양만큼 감염부위에 국소적으로 바름으로써 이루어지는 감염상처를 치료하는 방법.A method for treating a wound, which is achieved by topically applying the composition of claim 1 to an infected site in an effective amount. 제1항에 따른 조성물을 효과적인 양만큼 감염부위에 국소적으로 바름으로써 이루어지는 질감염을 치료하는 방법.A method for treating texturitis, which is achieved by topically applying the composition of claim 1 to an infected area in an effective amount. 제18항에 있어서, 그 감염이 질염 (Colpitis)임을 특징으로 하는 질 감염을 치료하는 방법. 그 조성물을 좌약으로 사용함을 특징으로 하는 질 감염을 치료하는 방법.19. The method of claim 18, wherein the infection is a colitis. A method of treating vaginal infections, characterized in that the composition is used as a suppository. 제19항에 있어서, 그 조성물을 좌약으로 사용함을 특징으로 하는 질 감염을 치료하는 방법.20. The method of claim 19, wherein the composition is used as a suppository. 제1항에 따른 조성물을 효과적인 양안큼 감염부위에 바름으로써 이루어지는 이염 (otitis)을 치료하는 방법.A method for treating otitis, which is achieved by applying the composition of claim 1 to an effective binocularly infected area. 제21항에 있어서, 그 조성물을 드롭프스(drops)의 형태로 감염환자의 귀에 사용함을 특징으로 하는 이염을 치료하는 방법,The method of claim 21, wherein the composition is used in the ear of an infected patient in the form of drops. 사람이나 동물환자에게 제1항에 따른 조성물을 효과적인 양만큼 투여함으로 이루어지는 유선염(mastitis)를 치료하는 방법.A method for treating mastitis by administering an effective amount of a composition according to claim 1 to a human or animal patient. 제23항에 있어서, 그 조성물을 주사기 주입에 의해 감염부위에 사용함을 특징으로 하는 유설염을 치료하는 방법.24. The method of claim 23, wherein the composition is used at the site of infection by syringe injection. 약으로 사용될 수 있는 리소짐 이할체와 리보핵산 분해효소 이합체로 구성된 그룹으로부터 선택된 이합체와 제약에 수용할 수 있는 담체로 이루어진 조성물.A composition comprising a dimer selected from the group consisting of lysozyme dimers and ribonuclease dimers, which can be used as drugs, and a carrier which can be accommodated in pharmaceuticals. 이합체 형태의 효소와 제약에 수용할순 있는 담체로 이루어진 항비루스성 또는 항박테리아성 조성물.An antiviral or antibacterial composition comprising an enzyme in dimeric form and a carrier acceptable to a pharmaceutical. ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.※ Note: The disclosure is based on the initial application.
KR1019900700132A 1988-05-26 1988-05-26 Antiviral or antibacterial compound Expired - Fee Related KR930004599B1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US1988/001785 WO1989011294A1 (en) 1988-05-26 1988-05-26 Antiviral or antibacterial compound and method of use

Publications (2)

Publication Number Publication Date
KR900701307A true KR900701307A (en) 1990-12-01
KR930004599B1 KR930004599B1 (en) 1993-06-01

Family

ID=35006604

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019900700132A Expired - Fee Related KR930004599B1 (en) 1988-05-26 1988-05-26 Antiviral or antibacterial compound

Country Status (4)

Country Link
KR (1) KR930004599B1 (en)
AR (1) AR240542A1 (en)
MY (1) MY106984A (en)
UA (1) UA26326C2 (en)

Also Published As

Publication number Publication date
UA26326C2 (en) 1999-08-30
MY106984A (en) 1995-08-30
KR930004599B1 (en) 1993-06-01
AR240542A1 (en) 1990-05-31

Similar Documents

Publication Publication Date Title
KR900701282A (en) Treatment, prevention of ischemic diseases of the heart or brain
BR0109336A (en) A medicament for the prevention, amelioration and / or treatment of a diabetic complication, a suitable or usable medicinal drug thereof, a method for preventing, ameliorating and / or treating a diabetic complication, and neuropathy, and uses of a sugar reducing agent. in postprandial blood and at least one agent selected from an antihypertensive agent, a vasodilating agent and an antihyperlipidemic agent
NL970006I2 (en) Use of indolone derivatives for the manufacture of medicines to treat Parkinson's disease.
KR900015742A (en) Antiviral agents
KR910005885B1 (en) Aqueous solution containing lysozyme chloride and dipotassium glycitride acid
BRPI9708706C8 (en) pharmaceutical composition for intravenous administration to a patient
ATE173627T1 (en) MEDICAL COMPOSITION
KR880007079A (en) Usage of 3'-dioxythymidine-2'-ene (3'-dioxy-2 ', 3'-didihydrothymidine) in the treatment of patients infected with retrovirus
SE8105561L (en) USE OF PYRIDOXIN-ALFA-KETOGLUTARATE IN PROPHYLAX OF HYPERMOOLIC ACIDEMA
KR970025615A (en) Cancer metastasis inhibitor
WO1991002529A2 (en) Product and method for killing abnormal vertebrate cells
JPH02204414A (en) Combination therapy by 2', 3'- dideoxypurine nucleoside/ purine nucleoside phosphorylase inhibitor and composition thereof
KR890001534A (en) Antibacterial FR109615 and its preparation method
WO2000016786A3 (en) Oxihumic acid and its use in the treatment of various conditions
UA49789C2 (en) Use of dimerised form of lysozyme for manufacture of medicament for inhibiting biosynthesis of tumor necrosis factor in animals and humans, method for prevention and treatment of diseases (variants), pharmaceutical formulations (variants), use of dimerised form of lysozyme for aids prevention and treatment
RU95105517A (en) APPLICATION OF THE DYMER OF LYSOZYME AS A MEDICINAL PRODUCT AND CONTAINING ITS COMPOSITIONS
KR900007434A (en) Therapeutics with cystatin as active ingredients
US4474759A (en) Method of treating bacterial, viral or parasitic diseases
KR900701307A (en) Antiviral or antibacterial compounds and methods of using the same
ES2148234T3 (en) PHARMACEUTICAL COMPOSITION BASED ON FLAVOPEREIRIN AND ITS USE IN THE TREATMENT OF HIV VIRUSES.
JPS58103324A (en) Interferon composition and use for herpes infection treatment
KR920703060A (en) Pharmaceutical Formulations
US4436732A (en) Medicated compound for treating diseases infected by virus of the herpes group
SU1629062A1 (en) Method for treatment of calves with colibacillosis
KR950702413A (en) Method of using 2- (4- (4-chlorophenyl) cyclohexyl) -3-hydroxy-1,4-naphthoquinone for cancer treatment (USE OF 2- (4- (4-CHLOROPHENYL) CYCLOHEXYL)- 3-HYDROXY-1,4-NAPHTHOQUINONE FOR THE TREATMENT OF CANCER)

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

G160 Decision to publish patent application
PG1605 Publication of application before grant of patent

St.27 status event code: A-2-2-Q10-Q13-nap-PG1605

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 7

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 8

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 9

FPAY Annual fee payment

Payment date: 20020708

Year of fee payment: 10

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 10

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20030602

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20030602